

Financial news for ARQL dated on 2019-12-23: A Perspective On Biopharma's Record M&A Run In 2019

Financial news for ARQL dated on 2019-12-15: The Week Ahead In Biotech: Avadel, Epizyme In Focus In A Quiet Week

Financial news for ARQL dated on 2019-12-12: The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls Clinical Pipeline, Tonix Snags Patent Win

Financial news for ARQL dated on 2019-12-11: Cantor Fitzgerald Says Thinks ArQule May See Other Bidders But Thinks Merck Makes A 'Great Strategic Fit,' Says Thinks Merck's Proposed Acquisition Is 'Fair'

Financial news for ARQL dated on 2019-12-11: The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint

Financial news for ARQL dated on 2019-12-10: Stocks That Hit 52-Week Highs On Tuesday

Financial news for ARQL dated on 2019-12-10: Benzinga's Top Upgrades, Downgrades For December 10, 2019

Financial news for ARQL dated on 2019-12-10: B. Riley Downgrades ArQule to Neutral, Raises Price Target to \$20

Financial news for ARQL dated on 2019-12-10: 10 Biggest Price Target Changes For Tuesday

Financial news for ARQL dated on 2019-12-10: Roth Capital Downgrades ArQule to Neutral

Financial news for ARQL dated on 2019-12-10: Cantor Fitzgerald Downgrades ArQule to Neutral, Raises Price Target to \$20

Financial news for ARQL dated on 2019-12-10: The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy \$3M In ContraFect Shares

Financial news for ARQL dated on 2019-12-10: H.C. Wainwright Downgrades ArQule to Neutral, Raises Price Target to \$20

Financial news for ARQL dated on 2019-12-10: RBC Capital Downgrades ArQule to Sector Perform, Raises Price Target to \$20

Financial news for ARQL dated on 2019-12-10: 80 Biggest Movers From Yesterday

Financial news for ARQL dated on 2019-12-09: Mid-Afternoon Market Update: Dow Falls 90 Points; XBiotech Shares Spike Higher

Financial news for ARQL dated on 2019-12-09: PreMarket Prep Recap: Small Biotech Firms Looking Healthy, Street Fades Macy's Downgrade

Financial news for ARQL dated on 2019-12-09: 48 Stocks Moving In Monday's Mid-Day Session

Financial news for ARQL dated on 2019-12-09: Mid-Day Market Update: Synthorx Jumps Following Acquisition News; Biocept Shares Plunge

Financial news for ARQL dated on 2019-12-09: Mid-Morning Market Update: Markets Mixed; Merck To Acquire ArQule For \$20/Share

Financial news for ARQL dated on 2019-12-09: Benzinga Pro's Top 5 Stocks To Watch For Mon., Dec. 9, 2019: MRK, PCG, M, DPLO, CHWY

Financial news for ARQL dated on 2019-12-09: 38 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for ARQL dated on 2019-12-09: 20 Stocks Moving In Monday's Pre-Market Session

Financial news for ARQL dated on 2019-12-09: ArQule To Be Acquired By Merck For \$2.7B

Financial news for ARQL dated on 2019-12-09: ArQule shares are trading higher after the company announced it would be acquired by Merck for \$20 per share in cash.

Financial news for ARQL dated on 2019-12-09: A Peek Into The Markets: US Stock Futures Down; Crude Oil Falls 1%

Financial news for ARQL dated on 2019-12-09: ArQule to be Acquired by Merck for \$20/Share Cash

Financial news for ARQL dated on 2019-12-07: The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling

Financial news for ARQL dated on 2019-12-06: Arqule Option Alert: Dec 20 \$16 Calls Sweep (2) near the Ask: 4975 @ \$0.57 vs 40 OI; Ref=\$9.81

Financial news for ARQL dated on 2019-12-05: Arqule Option Alert: Jan 17 \$11 Calls Sweep (38) near the Ask: 750 @ \$1.701 vs 1030 OI; Ref=\$9.815

Financial news for ARQL dated on 2019-12-05: Arqule Option Alert: Dec 20 \$11 Calls Sweep (28) near the Ask: 573 @ \$1.351 vs 812 OI; Ref=\$9.72

Financial news for ARQL dated on 2019-11-26: 45 Biggest Movers From Yesterday

Financial news for ARQL dated on 2019-11-25: 33 Stocks Moving In Monday's Mid-Day Session

Financial news for ARQL dated on 2019-11-25: ArQule shares are trading higher. The company earlier announced it will present clinical data from its Phase 1 study of ARQ 531 at the ASH Annual Meeting on December 9th.

Financial news for ARQL dated on 2019-11-25: ArQule Highlights Presentation Of Data For ARQ 531 At American Society of Hematology 2019 Annual Meeting Mon., Dec. 9, 2019

Financial news for ARQL dated on 2019-11-20: 77 Biggest Movers From Yesterday

Financial news for ARQL dated on 2019-11-19: Arqule Option Alert: Jan 17 \$12.5 Calls Sweep (3) near the Ask: 1625 @ \$0.191 vs 7219 OI; Ref=\$8.24

Financial news for ARQL dated on 2019-11-19: Arqule shares are trading higher. Not currently seeing any company-specific news.

Financial news for ARQL dated on 2019-11-18: Arqule Option Alert: Jan 17 \$7.5 Calls Sweep (30) near the Ask: 559 @ \$1.25 vs 8207 OI; Ref=\$7.82

Financial news for ARQL dated on 2019-11-07: 60 Biggest Movers From Yesterday

Financial news for ARQL dated on 2019-11-06: 62 Stocks Moving In Wednesday's Mid-Day Session

Financial news for ARQL dated on 2019-11-06: Arqule shares are trading lower after the company presented an abstract with early stage results of its reversible BTK inhibitor ARQ 531.

Financial news for ARQL dated on 2019-11-05: Benzinga's Top Upgrades, Downgrades For November 5, 2019

Financial news for ARQL dated on 2019-11-05: Wolfe Research Initiates Coverage On Arqule with Outperform Rating, Announces \$17 Price Target

Financial news for ARQL dated on 2019-11-04: Arqule Option Alert: Nov 15 \$9 Puts at the Ask: 4500 @ \$0.451 vs 4043 OI; Ref=\$9.69

Financial news for ARQL dated on 2019-10-31: Arqule shares are trading higher. Not seeing any news to justify the price action.

Financial news for ARQL dated on 2019-10-30: ArQule Sees FY19 EPS Guidance \$(0.35)-\$(0.37) Vs. \$(0.36) Est., Sales \$2M-\$5M Vs. \$3.55M Est.

Financial news for ARQL dated on 2019-10-30: Arqule Q3 EPS \$(0.09) Misses \$(0.08) Estimate, Sales \$208K Miss \$1.15M Estimate

Financial news for ARQL dated on 2019-10-30: The Daily Biotech Pulse: Novartis Program Placed On Partial Clinical Hold, Adcom Snub For Amag, Amgen Earnings

Financial news for ARQL dated on 2019-10-27: The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings

Financial news for ARQL dated on 2019-10-23: ArQule shares are trading lower on seemingly no company-specific news.

Financial news for ARQL dated on 2019-10-08: ArQule To Present Preclinical Data On Miransertib For The Treatment Of Vascular Malformations At The 2019 American Society Of Human Genetics (ASHG) Annual Meeting Oct. 15-19

Financial news for ARQL dated on 2019-10-03: Arqule shares are trading higher on continued momentum after the company dosed the first patient in its registrational MOSAIC trial of Miransertib.

Financial news for ARQL dated on 2019-10-02: Arqule shares are trading higher after the company dosed the first patient in its registrational MOSAIC trial of Miransertib.

Financial news for ARQL dated on 2019-10-02: ArQule Announces First Patient Dosed In Registrational MOSIAC Trial Of Miransertib For The Treatment Of Proteus Syndrome And PIK3CA-Related Overgrowth Spectrum

Financial news for ARQL dated on 2019-09-26: Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.

Financial news for ARQL dated on 2019-09-24: Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.

Financial news for ARQL dated on 2019-09-16: 22 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for ARQL dated on 2019-09-10: 84 Biggest Movers From Yesterday

Financial news for ARQL dated on 2019-09-05: Bleichroeder Reports 13.25% Passive Stake In Arqule

Financial news for ARQL dated on 2019-08-13: Shares of several healthcare companies are trading higher with the overall market after the U.S. announced it is excluding and delaying the additional 10% tariff on certain products.

Financial news for ARQL dated on 2019-08-07: Arqule shares are trading lower after the company reported worse-than-expected Q2 sales results.

Financial news for ARQL dated on 2019-08-07: The Daily Biotech Pulse: Novartis Stands By Zolgensma, GW Pharma Q2 Propelled By Epidiolex Sales, Ionis-Akcea Clinical Readout

Financial news for ARQL dated on 2019-08-07: Arqule Q2 EPS \$(0.08) Beats \$(0.09) Estimate, Sales \$281K Miss \$1.04M Estimate

Financial news for ARQL dated on 2019-08-06: Arqule's Earnings Preview

Financial news for ARQL dated on 2019-07-05: The Daily Biotech Pulse: FDA Approves Karyopharm's Blood Cancer Treatment, Grifols' Immunodeficiency Drug; ESMO, ISTH Conferences In The Spotlight

Financial news for ARQL dated on 2019-07-03: The Daily Biotech Pulse: Roche's Flu Drug Aces Late-Stage Trial, Acura Outlicenses Pain Medication, Neuronetics Gets New Finance Chief

Financial news for ARQL dated on 2019-07-02: The Daily Biotech Pulse: Celyad To Advance Leukemia Drug To Clinical Trial, Positive Data For Teva's Migraine Drug

Financial news for ARQL dated on 2019-06-26: The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to Depart

Financial news for ARQL dated on 2019-06-26: 51 Biggest Movers From Yesterday

Financial news for ARQL dated on 2019-06-25: 42 Stocks Moving In Tuesday's Mid-Day Session

Financial news for ARQL dated on 2019-06-25: 30 Stocks Moving In Tuesday's Pre-Market Session

Financial news for ARQL dated on 2019-06-25: The Daily Biotech Pulse: Genfit NASH Drug In China, Conatus Explores Sale, Gilead Stitches Up Immuno-Oncology Partnership

Financial news for ARQL dated on 2019-06-25: ArQule Prices 9.25M Share Offering At \$9.75/Share

Financial news for ARQL dated on 2019-06-24: ArQule shares are trading lower after the company filed for a mixed securities offering with no disclosed size.

Financial news for ARQL dated on 2019-06-24: ArQule Filing Shows Registration For Mixed Securities Offering, No Size Disclosed

Financial news for ARQL dated on 2019-06-21: The Daily Biotech Pulse: ContraVir's Volatile Ride Continues, Late-Stage Disappointment For Exelixis, Regeneron-Sanofi Breathe Easy

Financial news for ARQL dated on 2019-06-19: 36 Stocks Moving In Wednesday's Pre-Market Session

Financial news for ARQL dated on 2019-06-18: A Look At Benzinga Pro's Most-Searchd Tickers For June 18, 2019

Financial news for ARQL dated on 2019-06-18: 30 Stocks Moving In Tuesday's Pre-Market Session

Financial news for ARQL dated on 2019-06-18: The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale

Financial news for ARQL dated on 2019-06-18: 60 Biggest Movers From Yesterday

Financial news for ARQL dated on 2019-06-17: ArQule Hits 12-Year High Following Favorable Midstage Study Results

Financial news for ARQL dated on 2019-06-17: A Look At Benzinga Pro's Most-Searchd Tickers For June 17

Financial news for ARQL dated on 2019-06-17: 44 Stocks Moving In Monday's Mid-Day Session

Financial news for ARQL dated on 2019-06-17: ArQule Announces Preliminary Results from Its Phase 1/2 Study of Miransertib in Patients with PIK3CA-related Overgrowth Spectrum and Proteus syndrome in an Oral Presentation at the European Society of Human Genetics Conference

Financial news for ARQL dated on 2019-06-17: 46 Biggest Movers From Friday

Financial news for ARQL dated on 2019-06-15: The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs

Financial news for ARQL dated on 2019-06-14: Mid-Afternoon Market Update: Dow Turns Positive; India Globalization Capital Shares Spike Higher

Financial news for ARQL dated on 2019-06-14: A Look At Benzinga Pro's Most-Searchd Tickers For June 14

Financial news for ARQL dated on 2019-06-14: 35 Stocks Moving In Friday's Mid-Day Session

Financial news for ARQL dated on 2019-06-14: Mid-Day Market Update: Renren Drops After Q1 Results; ArQule Shares Surge

Financial news for ARQL dated on 2019-06-14: Benzinga Pro's Top 10 Most-Searchd Tickers For Morning of Fri., June 14, 2019

Financial news for ARQL dated on 2019-06-14: Mid-Morning Market Update: Markets Open Lower; Broadcom Cuts FY19 Outlook

Financial news for ARQL dated on 2019-06-14: Why Small-Cap Biotech ArQule Is Rallying

Financial news for ARQL dated on 2019-06-14: The Daily Biotech Pulse: Hematology And Rheumatology Conference Presentations Take The Spotlight, Eton In-Licenses Epilepsy Drug NDA

Financial news for ARQL dated on 2019-06-14: ArQule shares are trading higher after the company announced clinical proof-of-concept data from its ongoing Phase 1 study of ARQ-531 in patients with relapsed/refractory Hematologic Malignancies.

Financial news for ARQL dated on 2019-06-14: 26 Stocks Moving In Friday's Pre-Market Session

Financial news for ARQL dated on 2019-06-14: ArQule Shares Rise 35% Premarket on ARQ 531 Study Results; Shows Substantial Ant-Tumor Activity

Financial news for ARQL dated on 2019-06-14: ArQule Announces Clinical Proof-of-Concept Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies at #EHA19

Financial news for ARQL dated on 2019-06-10: ArQule Reports Will Present On Its Miransertib At European Society of Human Genetics Conference Jun. 15-18, 2019

Financial news for ARQL dated on 2019-06-08: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts

Financial news for ARQL dated on 2019-06-07: ArQule Reports Will Present Data For ARQ 531 To European Hematology Association

Financial news for ARQL dated on 2019-06-04: Shares of several healthcare companies

are trading higher with the overall US market. Recent comments out of China and Mexico has renewed trade optimism and lifted economic outlook.

Financial news for ARQL dated on 2019-05-24: Fast Money Halftime Report Picks For May 24

Financial news for ARQL dated on 2019-05-24: Foot Locker Option Alert: Jul 19 \$47.5 Calls Sweep (25) near the Ask: 826 @ \$1.45 vs 0 OI; Earnings 5/24 Before Open Ref=\$44.16 9:50:23 ARQL Arqule Option Alert: Jul 19 \$10 Calls Sweep (3) near the Ask: 8001 @ \$0.85 vs 2197 OI; Ref=\$7.65

Financial news for ARQL dated on 2019-05-24: Arqule Option Alert: Jul 19 \$10 Calls at the Ask: 1127 @ \$0.85 vs 2197 OI; Ref=\$7.52

Financial news for ARQL dated on 2019-05-24: The Daily Biotech Pulse: FDA Nod For Novocure, Dynavax Restructures, Therapix Receives Nasdaq Notice

Financial news for ARQL dated on 2019-05-22: The Tech Trader's 3 Stocks On The Move

Financial news for ARQL dated on 2019-05-17: 63 Biggest Movers From Yesterday

Financial news for ARQL dated on 2019-05-16: Shares of many Healthcare companies are trading higher as markets rebound from the recent volatility caused by uncertainty regarding US-China trade talks. Also, lawmakers were not able to pass a bill that would end 'surprise medical bills'.

Financial news for ARQL dated on 2019-05-16: 50 Stocks Moving In Thursday's Mid-Day Session

Financial news for ARQL dated on 2019-05-01: Arqule Option Alert: Jun 21 \$7.5 Calls Sweep (10) near the Ask: 714 @ \$1.0 vs 13087 OI; Earnings 5/1 Before Open Ref=\$6.5899

Financial news for ARQL dated on 2019-05-01: The Daily Biotech Pulse: Nabriva Stumbles At FDA Hurdle, Gilead CFO To Retire, Eisai Ends Collaboration With Purdue

Financial news for ARQL dated on 2019-05-01: ArQule Reaffirms FY19 Guidance: EPS \$(0.39)-\$(0.37) vs \$(0.37) Estimate, Sales \$3M-\$5M vs \$3.87M Est.

Financial news for ARQL dated on 2019-05-01: ArQule Q1 EPS \$(0.09) Misses \$(0.08) Estimate, Sales \$1.345M Miss \$2.1M Estimate

Financial news for ARQL dated on 2019-04-30: ArQule Announces Sinovant Science's Clinical Trial Application for Derazantinib Has Been Accepted by the Center for Drug Evaluation the the China National Medical Products Administration

Financial news for ARQL dated on 2019-04-24: Arqule Option Alert: Jun 21 \$10 Calls Sweep (21) near the Ask: 573 @ \$0.35 vs 422 OI; Earnings 5/6 Before Open [est] Ref=\$6.29

Financial news for ARQL dated on 2019-04-17: 40 Biggest Movers From Yesterday

Financial news for ARQL dated on 2019-04-15: Arqule Option Alert: Jun 21 \$7.5 Calls at the Ask: 9950 @ \$0.6 vs 1828 OI; Earnings 5/6 Before Open [est] Ref=\$5.525

Financial news for ARQL dated on 2019-04-15: Arqule Option Alert: Jun 21 \$5 Calls at the Ask: 1000 @ \$1.301 vs 2762 OI; Earnings 5/6 Before Open [est] Ref=\$5.55

Financial news for ARQL dated on 2019-04-11: UPDATE: RBC Initiates ArQule At Outperform As Firm Believes ARQ 531, ph.I BTK inhibitor, Has 'potential for an important role among the evolving B-cell cancer treatment paradigm and blockbuster BTK space where there is established but growing demand'

Financial news for ARQL dated on 2019-04-11: Benzinga's Top Upgrades, Downgrades For April 11, 2019

Financial news for ARQL dated on 2019-04-11: RBC Capital Initiates Coverage On Arqule with Outperform Rating, Announces \$9 Price Target

Financial news for ARQL dated on 2019-04-09: Arqule Option Alert: Apr 18 \$5 Calls at the Ask: 600 @ \$0.6 vs 1992 OI; Earnings 5/6 Before Open [est] Ref=\$5.46

Financial news for ARQL dated on 2019-04-02: ArQule To Present At 18th Annual Needham Healthcare Conference On April 9, 2019

Financial news for ARQL dated on 2019-03-15: ArQule Reports Pres, CFO, Treasurer Robert Weiskopf To Retire; Marc Schegerin Named Replacement

Financial news for ARQL dated on 2019-03-13: ArQule To Present At Oppenheimer's 29th Annual Healthcare Conference On March 20, 2019

Financial news for ARQL dated on 2019-03-08: 28 Stocks Moving In Friday's Pre-Market Session

Financial news for ARQL dated on 2019-03-08: Benzinga Pro Top 10 Most-Searched Tickers For Morning Of Fri., Mar. 8, 2019

Financial news for ARQL dated on 2019-03-08: 64 Biggest Movers From Yesterday

Financial news for ARQL dated on 2019-03-07: Benzinga Pro's Top 10 Most-Searched Tickers For Afternoon Of Thurs., Mar. 7, 2019

Financial news for ARQL dated on 2019-03-07: 51 Stocks Moving In Thursday's Mid-Day Session

Financial news for ARQL dated on 2019-03-07: Arqule shares are trading higher after the company reported better-than-expected Q4 sales; the company also provided FY19 sales guidance of \$3-\$5 million.

Financial news for ARQL dated on 2019-03-07: Daily Biotech Pulse: Allergan's Depression Drug Flunks Late-Stage Trial, Apellis Offering, ShockWave Medical IPO

Financial news for ARQL dated on 2019-03-07: ArQule Sees FY19 Sales \$3M-\$5M, Net Loss \$(0.39)-\$(0.37)

Financial news for ARQL dated on 2019-03-07: Arqule Q4 EPS \$(0.08) Misses \$(0.07) Estimate, Sales \$2.941M Beat \$1.82M Estimate

Financial news for ARQL dated on 2019-03-03: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs

Financial news for ARQL dated on 2019-02-25: ArQule Announces the Publication of Clinical Data of Miransertib Which the Company Says Supports Additional Development

Financial news for ARQL dated on 2019-01-24: 35 Stocks Moving In Thursday's Pre-Market Session

Financial news for ARQL dated on 2019-01-24: ArQule, Roche and Basilea Pharma Partner to Expore Derazantinib With Roche's Atezolizumab in Patients with Urothelial Cancer

Financial news for ARQL dated on 2019-01-15: 56 Biggest Movers From Yesterday

Financial news for ARQL dated on 2019-01-09: Arqule shares are trading higher after announcing positive results from its phase 2 oncology candidate.

Financial news for ARQL dated on 2019-01-09: ArQule's Partner, Basileia, Reports Interim Results From Phase 2 Study Of Its Derazantinib Oncology Candidate; Showed 21% Objective Response Rate, 83% Disease Control Tate And Confirmed Safety And Tolerability Profile

Financial news for ARQL dated on 2019-01-07: 58 Biggest Movers From Friday

Financial news for ARQL dated on 2018-12-27: 54 Biggest Movers From Yesterday

Financial news for ARQL dated on 2018-12-02: The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs

Financial news for ARQL dated on 2018-11-28: 48 Biggest Movers From Yesterday

Financial news for ARQL dated on 2018-11-16: The Daily Biotech Pulse: Mallinckrodt FDA Verdict, European Cheer For Bristol-Myers Squibb, Morphosys Clinches Licensing Deal

Financial news for ARQL dated on 2018-10-31: The Daily Biotech Pulse: KemPharm, FDA Nod For Merck, Clovis Q3 Miss, 3 Stocks To Debut

Financial news for ARQL dated on 2018-10-31: ArQule Worsens FY18 EPS Guidance From \$(0.14)-\$(0.10) To \$(0.17)-\$(0.14) vs \$(0.12) Estimate

Financial news for ARQL dated on 2018-10-31: ArQule, Inc. Q3 EPS \$(0.05) Beats \$(0.06) Estimate, Sales \$4.979M Beat \$2.26M Estimate

Financial news for ARQL dated on 2018-10-27: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs

Financial news for ARQL dated on 2018-10-22: Arqule Director Nussbaum Ran Buys 181,818 @ Avg Price: \$5.50

Financial news for ARQL dated on 2018-10-18: ArQule Shares Up 8.8% For Session;

Notable Biotech Sources Highlight 'Very Encouraging Data' For Rare Overgrowth Diseases Presented At American Society Of Human Genetics Meeting

Financial news for ARQL dated on 2018-10-18: ArQule Shares Spike ~10% Over Last Min.

Financial news for ARQL dated on 2018-10-17: The Daily Biotech Pulse: Eiger's Lymphoedema Drug Study Fails, Roche's Sales Rise

Financial news for ARQL dated on 2018-10-14: The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for ARQL dated on 2018-09-13: ArQule Reports FDA Granted Fast Track Designation For Treatment Of PIK3CA-Related Overgrowth Spectrum

Financial news for ARQL dated on 2018-09-12: 30 Stocks Moving In Wednesday's Pre-Market Session

Financial news for ARQL dated on 2018-08-15: 58 Biggest Movers From Yesterday

Financial news for ARQL dated on 2018-08-14: 45 Stocks Moving In Tuesday's Mid-Day Session

Financial news for ARQL dated on 2018-08-14: ArQule Late Monday Announced Publication Of Preclinical Data For ARQ 531 Reversible Inhibitor Of Both Wild Type And Mutant BTK; Shares Up 5.6%

Financial news for ARQL dated on 2018-08-02: 66 Biggest Movers From Yesterday

Financial news for ARQL dated on 2018-08-01: 60 Stocks Moving In Wednesday's Mid-Day Session

Financial news for ARQL dated on 2018-08-01: ArQule Shares Up 17% After Co. Announced Quarterly Earnings; EPS \$0.05 Beats \$0.03 Estimate, Sales \$13.71M Beat \$10.15M Estimate

Financial news for ARQL dated on 2018-08-01: Benzinga's Biotech Pulse: Pfizer's Xeljanx Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial

Financial news for ARQL dated on 2018-08-01: ArQule Raises FY18 Guidance: EPS From \$(0.24)-\$(0.18) To \$(0.14)-\$(0.10) vs \$(0.16) Estimate, Sales From \$14M-\$17M To \$21M-\$23M vs \$17M Est.

Financial news for ARQL dated on 2018-08-01: ArQule Q2 EPS \$0.05 Beats \$0.03 Estimate, Sales \$13.71M Beat \$10.15M Estimate

Financial news for ARQL dated on 2018-07-28: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

Financial news for ARQL dated on 2018-07-12: 44 Biggest Movers From Yesterday

Financial news for ARQL dated on 2018-07-11: 38 Stocks Moving In Wednesday's Mid-Day Session

Financial news for ARQL dated on 2018-07-11: Benzinga's Daily Biotech Pulse: Pfizer To Defer Price Hikes, Idera-BioCryst Merger Falls Through, ArQule To Offer Shares

Financial news for ARQL dated on 2018-07-11: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for ARQL dated on 2018-07-11: ArQule Prices \$60.5M Common Stock Offering At \$5.50/Share

Financial news for ARQL dated on 2018-07-10: ArQule Reports Offering Of Common Stock, No Size Disclosed

Financial news for ARQL dated on 2018-07-09: 34 Biggest Movers From Friday

Financial news for ARQL dated on 2018-07-06: Mid-Afternoon Market Update: Dow Rises 150 Points; Biogen Shares Climb On Positive Alzheimer's Drug Trial

Financial news for ARQL dated on 2018-07-05: A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year

Financial news for ARQL dated on 2018-06-26: Benzinga's Daily Biotech Pulse: Epidiolex, Roche's Influenza Drug Gets Priority Review Status, Xeris Jumps On Positive Trial Results

Financial news for ARQL dated on 2018-06-18: 26 Stocks Moving In Monday's Pre-Market Session

Financial news for ARQL dated on 2018-06-15: Benzinga's Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid Addiction Drug

Financial news for ARQL dated on 2018-06-15: UPDATE: ArQule Says 'ARQ 531 was well tolerated at all three dose levels, supporting continued dose escalation'

Financial news for ARQL dated on 2018-06-15: ArQule Reports Results From Ongoing Phase 1 Dose Escalation Study Of ARQ 531, Showed 'preliminary anti-tumor activity at all dose levels, resulting in an observed tumor reduction of 35% at 5mg, 33% at 10mg, and 29% at 15mg doses'

Financial news for ARQL dated on 2018-06-12: Oppenheimer Sees New Life In 22-Year-Old ArQule Stock

Financial news for ARQL dated on 2018-06-12: Benzinga's Top Upgrades, Downgrades For June 12, 2018

Financial news for ARQL dated on 2018-06-12: Oppenheimer Initiates Coverage On ArQule with Outperform Rating, Announces \$7 Price Target

Financial news for ARQL dated on 2018-06-07: ArQule To Present Clinical Data For BTK Inhibitor, ARQ 531, At 23rd Congress Of European Hematology Association (EHA)

Financial news for ARQL dated on 2018-05-30: ArQule Shares Volatile Over Last Few Mins.; Recently Saw 1.3M Share Block Trade At Price Of \$5/Share; Stock Up 3% For Session

Financial news for ARQL dated on 2018-05-29: 42 Biggest Movers From Friday

Financial news for ARQL dated on 2018-05-25: 33 Stocks Moving In Friday's Mid-Day Session

Financial news for ARQL dated on 2018-05-25: Benzinga's Daily Biotech Pulse: Biomarin Gets FDA Nod, Amarin Settles with Teva, Merck's Cancer Drug Review Extended

Financial news for ARQL dated on 2018-05-25: 26 Stocks Moving In Friday's Pre-Market Session

Financial news for ARQL dated on 2018-05-24: Benzinga's Daily Biotech Pulse: Eiger And Melinta Fall On Offerings, Apellis And Marinus Rise On Bullish Ratings

Financial news for ARQL dated on 2018-05-23: Benzinga's Daily Biotech Pulse: Insmed Presents Data, Pfenex Pulls Back On Offering, Oncolytics Listing

Financial news for ARQL dated on 2018-05-18: Benzinga's Daily Biotech Pulse: AstraZeneca's Q1, Novartis-Amgen Migraine Drug Approved

Financial news for ARQL dated on 2018-05-17: ArQule Shares Down 6.3% After Hours Following Registration For 10.629M Common Share Offering via Selling Holders

Financial news for ARQL dated on 2018-05-17: ArQule S-3 Shows Registration For 10.629M Common Share Offering via Selling Holders

Financial news for ARQL dated on 2018-05-07: ArQule Raises FY18 EPS Guidance From \$(0.34)-\$(0.30) to \$(0.24)-\$(0.18) vs \$(0.24) Est., Raises Sales Guidance from \$3M-\$4M to \$14M-\$17M vs \$8M

Financial news for ARQL dated on 2018-05-07: ArQule Q1 EPS \$(0.07) Misses \$(0.06) Estimate, Sales \$4.138M Beat \$2.11M Estimate

Financial news for ARQL dated on 2018-05-06: The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

Financial news for ARQL dated on 2018-04-18: 32 Biggest Movers From Yesterday

Financial news for ARQL dated on 2018-04-17: ArQule Shares Up ~13% After Co. Earlier Announced Agreement To License Derazantinib Outside Of China to Basilea Pharma

Financial news for ARQL dated on 2018-04-17: 27 Stocks Moving In Tuesday's Mid-Day Session

Financial news for ARQL dated on 2018-04-17: ArQule Shares Spike To Session Highs, Now Up 10.2%; Hearing Roth Capital Raised Price Target On Stock From \$5 To \$6, Buy Rating Reiterated

Financial news for ARQL dated on 2018-04-17: Benzinga Pro's 5 Stocks To Watch Today

Financial news for ARQL dated on 2018-04-17: 16 Stocks Moving In Tuesday's Pre-Market Session

Financial news for ARQL dated on 2018-04-17: ArQule Licenses Derazantinib to Basilea Pharma for Development and Commercialization Outside of China, Will Receive a \$10M Upfront Payment and Up to \$326M in Milestones

Financial news for ARQL dated on 2018-04-17: Basilea Licenses Late-stage Oncology Drug candidate Derazantinib from ArQule

Financial news for ARQL dated on 2018-04-16: 23 Stocks Moving In Monday's Pre-Market Session

Financial news for ARQL dated on 2018-04-13: The Week Ahead In Biotech: PDUFA Dates, IPOs And More

Financial news for ARQL dated on 2018-04-10: 40 Biggest Movers From Yesterday

Financial news for ARQL dated on 2018-04-09: 6 Stocks Moving In Monday's After-Hours Session

Financial news for ARQL dated on 2018-04-05: 8 Biotech Stocks With Clinical Trial Outcomes In April

Financial news for ARQL dated on 2018-04-03: 41 Biggest Movers From Yesterday

Financial news for ARQL dated on 2018-03-27: 8 Stocks Moving In Tuesday's After-Hours Session

Financial news for ARQL dated on 2018-03-27: 41 Biggest Movers From Yesterday

Financial news for ARQL dated on 2018-03-22: 33 Biggest Movers From Yesterday

Financial news for ARQL dated on 2018-03-21: 27 Stocks Moving In Wednesday's Mid-Day Session

Financial news for ARQL dated on 2018-03-15: Mid-Afternoon Market Update: Image Sensing Systems Gains Following Q4 Results; J.Jill Shares Plummet

Financial news for ARQL dated on 2018-03-08: Shares Of ArQule Volatile, Traders Circulating Jones Trading Comments On The Co. Saying 2 Upcoming Data Releases At American Association Of Cancer Research Could Be Catalysts For The Stock

Financial news for ARQL dated on 2018-03-05: ArQule Reports Q4 EPS \$(0.09) vs \$(0.09) Est., No Sales

Financial news for ARQL dated on 2018-03-05: Earnings Scheduled For March 5, 2018

Financial news for ARQL dated on 2018-02-22: Benzinga's Top Upgrades, Downgrades For February 22, 2018

Financial news for ARQL dated on 2018-02-22: Roth Capital Initiates Coverage On Arqule with Buy Rating, Announces \$5.00 Price Target

Financial news for ARQL dated on 2018-02-07: Roivant Sciences, ArQule Enter into License Agreement for Derazantinib in China; ArQule To Receive \$3M Upfront And \$2.5M In Additional Milestone Payment Within First Year

Financial news for ARQL dated on 2017-12-14: Needham Upgrades Arqule to Buy

Financial news for ARQL dated on 2017-12-06: Arqule Files For \$25,166,931M Shelf Offering By Selling Shareholders

Financial news for ARQL dated on 2017-11-15: ArQule Shares Down 3% Wed. Morning Despite Point72 13F From Tues. Afternoon Showing New 2M Share Stake In Co.; Stock Spiked Into Positive Territory Wed. Morning Around 9:55 a.m. EST, Has Since Made Parabolic Move Selling Off

Financial news for ARQL dated on 2017-11-09: ArQule Sees FY17 EPS \$(0.40)-\$(0.38) vs \$(0.43) Est.

Financial news for ARQL dated on 2017-11-09: ArQule Reports Q3 EPS \$(0.09) vs \$(0.11) Est.

Financial news for ARQL dated on 2017-11-01: ArQule Reports FDA Granted Rare Pediatric Disease Designation For Co.'s ARQ-092 For Treatment Of Proteus Syndrome

Financial news for ARQL dated on 2017-10-16: A Peek Into The Markets: U.S. Stock Futures Edge Higher; Netflix Earnings In Focus

Financial news for ARQL dated on 2017-10-16: ArQule Announces a \$15.7M Private Placement from Stock and Warrants

Financial news for ARQL dated on 2017-10-16: ArQule Reports \$15.7M Private Placement of Common Stock

Financial news for ARQL dated on 2017-09-07: ArQule CEO Buys 16,397 @ Avg Price: \$1.15 -Form4

Financial news for ARQL dated on 2017-09-06: ArQule CEO Buys 19,156 @ Avg Price: \$1.14 (Form4)

Financial news for ARQL dated on 2017-08-04: ArQule Reports Q2 \$(0.10) vs \$(0.11) Est.

Financial news for ARQL dated on 2017-07-11: ArQule Doses First Patient in Phase 1 Trial of ARQ 531

Financial news for ARQL dated on 2017-06-23: ArQule To Offer Preclinical Data For ARQ 531 At EHA: '...demonstrates potent anti-tumor activity in DLBCL'

Financial news for ARQL dated on 2017-06-07: ArQule Reports First Patient Dosed in Co. Sponsored Phase 1/2 Trial of ARQ 092 for Rare Overgrowth Diseases

Financial news for ARQL dated on 2017-06-03: ArQule Presents Phase 1/2 Clinical Data with ARQ 087 in Intrahepatic Cholangiocarcinoma #ASCO17

Financial news for ARQL dated on 2017-06-02: ArQule Pops to High on Volume

Financial news for ARQL dated on 2017-05-03: ArQule Reports Q1 EPS \$(0.11), Inline

Financial news for ARQL dated on 2017-04-26: ArQule Earlier Announced Issuance of US Patent Covering Composition of Matter of ARQ 531

Financial news for ARQL dated on 2017-04-11: ArQule Gets FDA Clearance to Conduct Phase 1 ARQ 531 Trial

Financial news for ARQL dated on 2017-04-11: ArQule Receives Clearance of Investigational New Drug Application For ARQ 531

Financial news for ARQL dated on 2017-03-27: ArQule Reports Phase 3 JET-HCC Trial Did Not Meet Primary Endpoint In PFS Between tivantinib and Placebo Group

Financial news for ARQL dated on 2017-03-07: ArQule Reports Q4 EPS \$(0.10) vs. \$(0.10), Sales \$1.18M vs. \$910K Est.

Financial news for ARQL dated on 2017-02-17: 18 Biggest Mid-Day Losers For Friday

Financial news for ARQL dated on 2016-12-03: ArQule Announces Preclinical Data on ARQ 092, Demonstrating Effectiveness in the Treatment of Sickle Cell Disease Presented at ASH 2016

Financial news for ARQL dated on 2016-11-07: ArQule Q3 EPS \$(0.08) vs \$(0.09) Est, Revenue \$1.22M vs \$1.10M Est

Financial news for ARQL dated on 2016-11-07: ArQule Reports Q3 EPS \$(0.08) vs. Est. \$(0.09), Rev. \$1.223M vs. Est. \$1.1M

Financial news for ARQL dated on 2016-09-02: ArQule Files For 100M Mixed Shelf

Financial news for ARQL dated on 2016-08-03: ArQule Reports Q2 EPS (\$0.07) vs. Est. \$(0.08), Rev. \$1.072M vs. Est. \$1.13M

Financial news for ARQL dated on 2016-08-03: ArQule Reports Q2 EPS \$(0.07) vs \$(0.08) Est., Sales \$1.072M vs \$1.13M Est.

Financial news for ARQL dated on 2016-07-18: ArQule Presents Preclinical Data for ARQ 531, Data supports further preclinical and clinical research in BTK sensitive and ibrutinib resistant malignancies

Financial news for ARQL dated on 2016-06-30: ArQule Reports 75% Disease Control Rate, With 25% Objective Response Rate Observed In 12 Of 21 Patients Harboring FGFR2 Genetic Alterations

Financial news for ARQL dated on 2016-05-04: ArQule Reports Q1 EPS \$(0.08) vs. Est. \$(0.07), Rev. \$1.227M vs. Est. \$1.63M

Financial news for ARQL dated on 2016-03-22: ArQule Reports Deal with Daiichi Sankyo

for Continuation of METIV-HCC Phase 3 Study of Tivantinib in Second-Line Hepatocellular Cacinoma

Financial news for ARQL dated on 2016-02-29: ArQule Sees FY16 Sales \$4M-\$5M vs \$7.2M Est., EPS \$(0.43)-\$(0.38) vs \$(0.32) Est.

Financial news for ARQL dated on 2016-02-29: ArQule Reports Q4 EPS \$(0.05) vs \$(0.06) Est., R&D Sales \$2.797M vs \$2.55M Est.

Financial news for ARQL dated on 2016-02-29: ArQule Sees FY 2016 EPS \$(0.38)-\$(0.43) Vs Est \$(0.32) & Sales \$4.0M-\$5.0M Vs Est \$7.15M

Financial news for ARQL dated on 2016-02-29: ArQule Reports Q4 EPS \$(0.05) Vs Est \$(0.06)

Financial news for ARQL dated on 2016-02-29: ArQule Announces \$15.3M Offering

Financial news for ARQL dated on 2016-01-25: ArQule Shows Phase 2 Study and Ongoing Phase 3 Data On Tivantinib In Hepatocellular Carcinoma

Financial news for ARQL dated on 2016-01-08: 12 Biotechs With Binary Events Coming This Year

Financial news for ARQL dated on 2015-12-21: Benzinga's Top Upgrades

Financial news for ARQL dated on 2015-12-21: RBC Capital Upgrades ArQule to Outperform

Financial news for ARQL dated on 2015-12-15: UPDATE: ArQule Says 'Additional response in phase 1b further validates development for ARQ 087 in cancers with FGFR2 genetic alterations'

Financial news for ARQL dated on 2015-12-15: ArQule Reports Orphan Drug Designation in Cholangiocarcinoma, Offers Clinical Update for ARQ 087

Financial news for ARQL dated on 2015-12-10: ArQule, Daiichi Sankyo Reports Closing of Accural in METIV-HCC Phase 3 Trial of Tivantinib

Financial news for ARQL dated on 2015-11-11: ArQule Gets FDA Orphan Designation for Treatment of Proteus Syndrome

Financial news for ARQL dated on 2015-11-04: ArQule Reports Q3 Loss of \$0.04/Share vs Loss of \$0.08/Share Est.; Sees FY15 Sales \$10M-\$11M vs \$11.4M Est., Loss of \$0.24-\$0.21/Share vs Loss of \$0.29/Share Est.

Financial news for ARQL dated on 2015-10-15: ArQule Reports Pre-Clinical Data of AKT Inhibitor ARQ 092, ARQ 751 Supports Use of AKT1, PI3K Mutations as Biomarkers

Financial news for ARQL dated on 2015-09-28: ArQule Presents Results From Phase 1b Expansion Study of ARQ 092 at the 2015 European Cancer Conference

Financial news for ARQL dated on 2015-09-08: ArQule Presents Additional Clinical Biomarker Data From Phase 2 Study of Tivantinib in Hepatocellular Carcinoma at International Liver Cancer Association Conference

Financial news for ARQL dated on 2015-08-05: ArQule Reports Q2 EPS \$(0.06) vs. Est. \$(0.08), Rev. 3.004M vs. Est. \$2.5M

Financial news for ARQL dated on 2015-07-06: ArQule Reports Interim Phase 2 Study Results for Tivantinib in Combination with Cetuximab in Patients with MET-High, KRAS Wild Type Colorectal Cancer Presented at ESMO World Congress on Gastrointestinal Cancer 2015

Financial news for ARQL dated on 2015-06-01: ArQule Names Robert Weiskopf CFO

Financial news for ARQL dated on 2015-05-06: ArQule Reports Q1 Loss of \$0.07/Share vs Loss of \$0.08/Share Est.

Financial news for ARQL dated on 2015-03-18: Benzinga's Top #PreMarket Gainers

Financial news for ARQL dated on 2015-03-04: ArQule Q4 EPS -\$0.06, Revenue \$3.02M

Financial news for ARQL dated on 2014-11-17: ArQule Chairman Zenner Buys 20,830 Shares @\$1.20/Share -Form 4

Financial news for ARQL dated on 2014-11-11: ArQule Announces Collaboration With NIH For Clinical Development Of ARQ 092 In Proteus Syndrome

Financial news for ARQL dated on 2014-11-10: Morning Market Movers

Financial news for ARQL dated on 2014-11-10: ArQule, Inc. Reports Q3 EPS of \$(0.10) vs \$(0.13) Est; Revenue of \$2.66M vs \$2.20M Est

Financial news for ARQL dated on 2014-08-05: ArQule, Inc. Sees FY2014 EPS \$(0.48)-(0.52); Sees Sales \$8.0M-10.0M

Financial news for ARQL dated on 2014-08-05: ArQule, Inc. Reports Q2 EPS of \$(0.10) vs \$(0.12) Est; Revenue of \$2.90M vs \$2.43M Est

Financial news for ARQL dated on 2014-06-02: Corporate Events for the Week of Jun. 2nd, 2014

Financial news for ARQL dated on 2014-05-23: Morning Market Movers Friday, May 23, 2014

Financial news for ARQL dated on 2014-05-22: Now Will Replace General Cable, Civeo Will Replace Matthews Int'l in S&P MidCap 400, UTI Worldwide Will Replace ArQule in S&P SmallCap 600

Financial news for ARQL dated on 2014-05-07: ArQule, Inc. Reports Q1 EPS of \$(0.11), Inline

Financial news for ARQL dated on 2014-04-14: Stocks Hitting 52-Week Lows

Financial news for ARQL dated on 2014-03-05: ArQule, Inc. Sees FY2014 EPS \$(0.48)-(0.52) vs \$(0.43) Est; Sees Sales \$8.0M-10.0M vs \$13.20M Est

Financial news for ARQL dated on 2014-03-05: Earnings Scheduled For March 5, 2014

Financial news for ARQL dated on 2014-02-04: ArQule Reports Commencement of Phase 3 Clinical Trial with Tivantinib in Hepatocellular Carcinoma by Partner Kyowa Hakko Kirin in Japan

Financial news for ARQL dated on 2014-01-17: Benzinga's Top #PreMarket Gainers

Financial news for ARQL dated on 2014-01-16: ArQule Says Data Monitoring Committee Okays Continuation of Phase 3 METIV-HCC Study

Financial news for ARQL dated on 2013-11-07: ArQule, Inc. Sees FY2013 EPS \$(0.42)-(0.46) vs \$(0.48) Est; Sees Sales \$13.0M-16.0M vs \$15.41M Est

Financial news for ARQL dated on 2013-11-07: ArQule, Inc. Reports Q3 EPS of \$(0.10) vs \$(0.13) Est; Revenue of \$3.54M vs \$2.77M Est

Financial news for ARQL dated on 2013-09-27: Benzinga's Top Pre-Market Gainers

Financial news for ARQL dated on 2013-09-18: UPDATE: Citigroup Downgrades ArQule on Increased Uncertainty Around Lead Cancer Drug Candidate

Financial news for ARQL dated on 2013-09-18: Citigroup Downgrades ArQule, Inc. to Neutral, Lowers PT to \$2.25

Financial news for ARQL dated on 2013-09-03: Lazard Capital Markets Downgrades ArQule, Inc. to Neutral

Financial news for ARQL dated on 2013-09-03: Morning Market Losers

Financial news for ARQL dated on 2013-07-30: ArQule, Inc. Sees FY2013 Sales \$12.0M-15.0M

Financial news for ARQL dated on 2013-07-30: ArQule, Inc. Reports Q2 EPS of \$(0.11) vs \$(0.12) Est; Revenue of \$4.44M vs \$3.84M Est

Financial news for ARQL dated on 2013-06-01: ArQule Announces Phase 2 Study Results for Tivantinib in Combination with Cetuximab and Irinotecan for Colorectal Cancer at ASCO

Financial news for ARQL dated on 2013-05-08: ArQule, Inc. Reports Q1 EPS of \$(0.09) vs \$(0.11) Est

Financial news for ARQL dated on 2013-05-01: First Manhattan Responds to VIVUS Board Additions, Says Board Still Needs Overhaul

Financial news for ARQL dated on 2013-04-01: ArQule Regains Worldwide Rights to AKT Program

Financial news for ARQL dated on 2013-03-14: ArQule, Inc. Sees FY2013 EPS \$0.45-0.50 vs \$0.49 Est; Sees Sales \$12.0M-15.0M vs \$22.90M Est

Financial news for ARQL dated on 2013-03-14: ArQule, Inc. Reports Q4 EPS of \$(0.09) vs \$(0.13) Est; Revenue of \$5.14M vs \$5.17M Est

Financial news for ARQL dated on 2013-03-14: Earnings Scheduled For March 14, 2013

Financial news for ARQL dated on 2013-01-14: ArQule Shares Fall After MLV Downgrade to Hold

Financial news for ARQL dated on 2013-01-11: Arqul Resumes Trading

Financial news for ARQL dated on 2013-01-11: PREVIEW: ArQule to Resume Trading at 8:00 AM ET

Financial news for ARQL dated on 2013-01-11: Daiichi Sankyo and ArQule Announce Phase 2 Trial with Tivantinib in Colorectal Cancer Did Not Meet Primary Endpoint

Financial news for ARQL dated on 2013-01-11: ArQule Halted; Pending News

Financial news for ARQL dated on 2012-12-13: ArQule Enrolls First Patient in Phase 1 Trial with ARQ 087

Financial news for ARQL dated on 2012-11-27: Burril Maintains Arqule at Market Outperform, Lowers PT from \$10.00 to \$5.00

Financial news for ARQL dated on 2012-11-27: Edison Investment Research Initiates Coverage PT on Arqule to \$5.40

Financial news for ARQL dated on 2012-11-08: ArQule Announces Chief Scientific Officer Thomas Chan to Leave Co.

Financial news for ARQL dated on 2012-11-01: ArQule Sees FY12 EPS \$(0.20)-(0.25) vs \$(0.26) Est, Sales \$34-37M vs \$41.9M Est

Financial news for ARQL dated on 2012-11-01: Arqule Reports Q3 EPS \$-0.01 vs \$-0.07 Est; Revenues \$10.94M vs \$10.61M Est

Financial news for ARQL dated on 2012-10-26: UPDATE: Citigroup Initiates ArQule at Buy

Financial news for ARQL dated on 2012-10-25: Citigroup Initiates Coverage on ArQule at Buy, Announces PT of \$5

Financial news for ARQL dated on 2012-10-16: ArQule and Daiichi Sankyo Reach Agreement with FDA on Special Protocol Assessment for Phase 3 Trial of Tivantinib in Hepatocellular Carcinoma

Financial news for ARQL dated on 2012-10-04: Benzinga's Top Pre-Market Gainers

Financial news for ARQL dated on 2012-10-03: RBC Capital Markets Downgraded Arqule from Outperform to Sector Perform

Financial news for ARQL dated on 2012-10-02: Stocks Hitting 52-Week Lows

Financial news for ARQL dated on 2012-10-02: Morning Market Losers

Financial news for ARQL dated on 2012-10-02: FROM EARLIER: Arqule and Daiichi Sankyo Announce Discontinuation of Phase 3 Trail

Financial news for ARQL dated on 2012-10-02: Benzinga's Top Pre-Market Losers

Financial news for ARQL dated on 2012-09-12: UPDATE: Burrill & Company Initiates Outperform, \$10 PT on ArQule

Financial news for ARQL dated on 2012-09-12: Burrill & Company Initiates Coverage on Arqule at Market Outperform, Announces PT of \$10

Financial news for ARQL dated on 2012-09-04: Option Alert: Arqule January 2013 10/12.5 Call Spread; Block Trade: 2,400/4,800 Contracts; Currently \$5.24

Financial news for ARQL dated on 2012-08-02: Arqule Reports Q2 EPS \$-0.01 vs \$-0.07 Est; Revenues \$11.8M vs \$9.84M Est

Financial news for ARQL dated on 2012-06-11: Five Stocks With Heavy Insider Trading

Financial news for ARQL dated on 2012-06-02: ArQule Announces Positive Phase 2 Study Results for Tivantinib in Previously Treated Hepatocellular Carcinoma

Financial news for ARQL dated on 2012-05-18: ArQule and Daiichi Sankyo Announce

Completion of Patient Recruitment in Phase 3 Clinical Trial of Tivantinib in Non-Small Cell Lung Cancer

Financial news for ARQL dated on 2012-05-17: Positive Phase 2 Clinical Data with Tivantinib in Hepatocellular Carcinoma

Financial news for ARQL dated on 2012-05-03: ArQule Reports Q1 EPS \$-0.08 vs \$-0.07 Est; Revenues \$8.5M vs \$10.01M Est

Financial news for ARQL dated on 2012-04-11: ArQule Prices Public Offering of Common Stock; Says 7.15M Shares Priced at \$7.30

Financial news for ARQL dated on 2012-04-10: ArQule Announces Proposed Public Offering 6M Shares

Financial news for ARQL dated on 2012-03-15: UPDATE: Stifel Nicolaus Initiates Buy, \$13 Target on ArQule

Financial news for ARQL dated on 2012-03-15: Stifel Nicolaus Maintains ArQule at Buy, Announces PT of \$13

Financial news for ARQL dated on 2012-01-17: ArQule Up 15% After Liver Cancer Drug Meets Endpoints

Financial news for ARQL dated on 2012-01-17: ArQule Spiking Higher

Financial news for ARQL dated on 2012-01-17: ArQule Announces Tivantinib Meets Primary Endpoint, Significantly Extending Time to Progression in Phase 2 Trial in Second-Line Hepatocellular Carcinoma

Financial news for ARQL dated on 2011-11-10: Oppenheimer Comments on ArQule

Financial news for ARQL dated on 2011-08-15: MLV Maintains Buy on ArQule

Financial news for ARQL dated on 2011-05-26: UPDATE: Global Hunter Initiates ArQule at Accumulate

Financial news for ARQL dated on 2011-05-05: ArQule Reports EPS of \$(0.03) vs. \$(0.08) Estimate; Revenues \$13.4M vs. \$11.07M Estimate

Financial news for ARQL dated on 2011-04-28: ArQule, Inc. Announces Appointment of Dr. Susan Kelley to Board of Directors (ARQL)

Financial news for ARQL dated on 2011-03-01: ArQule Reports Q4 Loss of \$0.13 per share

Financial news for ARQL dated on 2011-01-20: ArQule Prices 7M Share Offering at \$6.15

Financial news for ARQL dated on 2011-01-19: ArQule Announces Public Offering of Common Stock

Financial news for ARQL dated on 2010-10-11: ArQule and Daiichi Sankyo Reach Agreement with FDA

Financial news for ARQL dated on 2010-10-01: ArQule Initiated At Outperform

Financial news for ARQL dated on 2010-06-07: Early Volume Plays Among Those Valued Below \$10 (BPAX, ARQL, KRY, S)

Financial news for ARQL dated on 2010-05-27: Oppenheimer Maintains ArQule (ARQL) Outperform Rating

Financial news for ARQL dated on 2010-03-31: Market Roundup (BBI, BA, AIG, PUK, ARQL, F)

Financial news for ARQL dated on 2010-03-31: Benzinga's Top Pre-Market Gainers (ARQL, AIXG, ISIS, ORCT)

Financial news for ARQL dated on 2010-03-21: How Will Obama-Care Play Into The Markets And ETFs?